Follicular lymphoma (FL) is an indolent lymphoma associated with follicular centre B cells and typically contains the Bcl-2 chromosomal translocation t(14;18). FLs are sensitive to chemotherapy; however, the majority of patients eventually die from the disease. Thus, there is a need for new, less toxic and more active treatments. Enzastaurin (LY317615.HCl), an acyclic bisindolylmaleimide, was initially developed as an ATP-competitive selective inhibitor of PKC. Enzastaurin was shown to target the phosphoinositide 3-kinase (PI3K)/AKT pathway and to inactivate BAD, a pro-apoptotic member of the Bcl-2 family proteins. We recently investigated the effect of enzastaurin on proliferation and survival of myeloma and lymphoma cell lines[1,2]. We found that enzastaurin inhibits cell proliferation and induces apoptosis.